Practical recommendations for using ctDNA in clinical decision making
Published 2023 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Practical recommendations for using ctDNA in clinical decision making
Authors
Keywords
-
Journal
NATURE
Volume 619, Issue 7969, Pages 259-268
Publisher
Springer Science and Business Media LLC
Online
2023-07-13
DOI
10.1038/s41586-023-06225-y
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Kinetics of postoperative circulating cell-free DNA and impact on minimal residual disease detection rates in patients with resected stage I-III colorectal cancer.
- (2023) Stacey A. Cohen et al. JOURNAL OF CLINICAL ONCOLOGY
- Molecular residual disease and efficacy of adjuvant chemotherapy in patients with colorectal cancer
- (2023) Daisuke Kotani et al. NATURE MEDICINE
- Circulating tumor DNA‐based molecular residual disease detection for treatment monitoring in advanced melanoma patients
- (2023) Zeynep Eroglu et al. CANCER
- Cell-free DNA analysis in current cancer clinical trials: a review
- (2022) M. Cisneros-Villanueva et al. BRITISH JOURNAL OF CANCER
- NRG-GI008: Colon adjuvant chemotherapy based on evaluation of residual disease (CIRCULATE-US).
- (2022) Arvind Dasari et al. JOURNAL OF CLINICAL ONCOLOGY
- Assessment of Molecular Residual Disease Using Circulating Tumor DNA to Identify Multiple Myeloma Patients at High Risk of Relapse
- (2022) Binod Dhakal et al. Frontiers in Oncology
- Residual ctDNA after treatment predicts early relapse in patients with early-stage non-small cell lung cancer
- (2022) D. Gale et al. ANNALS OF ONCOLOGY
- Abstract P2-01-10: Detection of ctDNA following surgery predicts relapse in breast cancer patients receiving primary surgery
- (2022) Isaac Garcia-Murillas et al. CANCER RESEARCH
- Final Results of Neoadjuvant Atezolizumab in Cisplatin-ineligible Patients with Muscle-invasive Urothelial Cancer of the Bladder
- (2022) Bernadett Szabados et al. EUROPEAN UROLOGY
- A clinician’s handbook for using ctDNA throughout the patient journey
- (2022) Samantha O. Hasenleithner et al. Molecular Cancer
- Evaluation of Comparative Surveillance Strategies of Circulating Tumor DNA, Imaging, and Carcinoembryonic Antigen Levels in Patients With Resected Colorectal Cancer
- (2022) Marwan Fakih et al. JAMA Network Open
- Treatment Response Monitoring Using a Tumor-Informed Circulating Tumor DNA Test in an Advanced Triple-Negative Breast Cancer Patient: A Case Report
- (2022) Georges Azzi et al. Case Reports in Oncology
- Serial postoperative ctDNA monitoring of breast cancer recurrence.
- (2022) Jacqueline Shaw et al. JOURNAL OF CLINICAL ONCOLOGY
- Using Circulating Tumor DNA in Colorectal Cancer: Current and Evolving Practices
- (2022) Midhun Malla et al. JOURNAL OF CLINICAL ONCOLOGY
- Circulating tumour DNA — looking beyond the blood
- (2022) Ann Tivey et al. Nature Reviews Clinical Oncology
- Circulating Tumor DNA Analysis Guiding Adjuvant Therapy in Stage II Colon Cancer
- (2022) Jeanne Tie et al. NEW ENGLAND JOURNAL OF MEDICINE
- Practical Considerations for the Use of Circulating Tumor DNA in the Treatment of Patients With Cancer
- (2022) Matthew G. Krebs et al. JAMA Oncology
- Genotype-specific differences in circulating tumor DNA levels in advanced NSCLC
- (2021) Vincent K. Lam et al. Journal of Thoracic Oncology
- The watch-and-wait strategy versus surgical resection for rectal cancer patients with a clinical complete response after neoadjuvant chemoradiotherapy
- (2021) Qiao-xuan Wang et al. Radiation Oncology
- Updates on liquid biopsy: current trends and future perspectives for clinical application in solid tumors
- (2021) Pamela Pinzani et al. CLINICAL CHEMISTRY AND LABORATORY MEDICINE
- Clinical Value of ctDNA in Hematological Malignancies (Lymphomas, Multiple Myeloma, Myelodysplastic Syndrome, and Leukemia): A Meta-Analysis
- (2021) Xiangyu Tan et al. Frontiers in Oncology
- Circulating Tumor DNA as a Predictive Biomarker in Adjuvant Chemotherapy for Patients with Stage 2A Colon Cancer (COBRA)
- (2021) Emily A. Verbus et al. ANNALS OF SURGICAL ONCOLOGY
- CIRCULATE‐Japan: Circulating tumor DNA–guided adaptive platform trials to refine adjuvant therapy for colorectal cancer
- (2021) Hiroya Taniguchi et al. CANCER SCIENCE
- Minimal Residual Disease Detection using a Plasma-Only Circulating Tumor DNA Assay in Colorectal Cancer Patients
- (2021) Aparna R. Parikh et al. CLINICAL CANCER RESEARCH
- Early plasma circulating tumor DNA (ctDNA) changes predict response to first-line pembrolizumab-based therapy in non-small cell lung cancer (NSCLC)
- (2021) Biagio Ricciuti et al. Journal for ImmunoTherapy of Cancer
- Role of Circulating Tumor DNA in Hematological Malignancy
- (2021) Miho Ogawa et al. Cancers
- Circulating tumor DNA and magnetic resonance imaging to predict neoadjuvant chemotherapy response and recurrence risk
- (2021) Mark Jesus M. Magbanua et al. npj Breast Cancer
- Clinical validation of a targeted methylation-based multi-cancer early detection test using an independent validation set
- (2021) E.A. Klein et al. ANNALS OF ONCOLOGY
- The CIRCULATE trial: Circulating tumour DNA based decision for adjuvant treatment in colon cancer stage II evaluation (AIO-KRK-0217)
- (2021) Gunnar Folprecht et al. Clinical Colorectal Cancer
- ctDNA guiding adjuvant immunotherapy in urothelial carcinoma
- (2021) Thomas Powles et al. NATURE
- Clinical correlates of circulating cell-free DNA tumor fraction
- (2021) Joerg Bredno et al. PLoS One
- Longitudinal Circulating Tumor DNA Analysis in Blood and Saliva for Prediction of Response to Osimertinib and Disease Progression in EGFR-Mutant Lung Adenocarcinoma
- (2021) Chul Kim et al. Cancers
- Prediction of pathological response following neoadjuvant chemotherapy in patients with muscle-invasive bladder cancer: the PRE-PREVENCYS trial
- (2021) F. J. Hinsenveld et al. BMC CANCER
- Circulating Tumor DNA in Stage III Colorectal Cancer, beyond Minimal Residual Disease Detection, toward Assessment of Adjuvant Therapy Efficacy and Clinical Behavior of Recurrences
- (2021) Tenna Vesterman Henriksen et al. CLINICAL CANCER RESEARCH
- Commercial ctDNA Assays for Minimal Residual Disease Detection of Solid Tumors
- (2021) Kevin Chen et al. Molecular Diagnosis & Therapy
- Early assessment of circulating tumor DNA after curative‐intent resection predicts tumor recurrence in early‐stage and locally advanced non‐small‐cell lung cancer
- (2021) Silvia Waldeck et al. Molecular Oncology
- Dynamic recurrence risk and adjuvant chemotherapy benefit prediction by ctDNA in resected NSCLC
- (2021) Bin Qiu et al. Nature Communications
- ctDNA: An emerging neoadjuvant biomarker in resectable solid tumors
- (2021) Christopher Abbosh et al. PLOS MEDICINE
- Circulating Tumor DNA as a Predictive Marker of Recurrence for Patients With Stage II-III Breast Cancer Treated With Neoadjuvant Therapy
- (2021) Po-Han Lin et al. Frontiers in Oncology
- Circulating Tumor DNA and Minimal Residual Disease (MRD) in Solid Tumors: Current Horizons and Future Perspectives
- (2021) Yan Peng et al. Frontiers in Oncology
- A careful reassessment of anthracycline use in curable breast cancer
- (2021) Sara Alsterlind Hurvitz et al. npj Breast Cancer
- Clinical utility of circulating tumor DNA as a response and follow-up marker in cancer therapy
- (2020) Pieter A. Boonstra et al. CANCER AND METASTASIS REVIEWS
- Sensitive Detection of Minimal Residual Disease in Patients Treated for Early-Stage Breast Cancer
- (2020) Heather A. Parsons et al. CLINICAL CANCER RESEARCH
- The PEGASUS trial: Post-surgical liquid biopsy-guided treatment of stage III and high-risk stage II colon cancer patients.
- (2020) Sara Lonardi et al. JOURNAL OF CLINICAL ONCOLOGY
- The effect of surgical trauma on circulating free DNA levels in cancer patients – implications for studies of circulating tumor DNA
- (2020) Tenna V. Henriksen et al. Molecular Oncology
- Immune-related adverse events of checkpoint inhibitors
- (2020) Manuel Ramos-Casals et al. Nature Reviews Disease Primers
- Circulating tumor DNA clearance predicts prognosis across treatment regimen in a large real-world longitudinally monitored advanced non-small cell lung cancer cohort
- (2020) Yong Song et al. Translational Lung Cancer Research
- Localised Colon Cancer: ESMO Clinical Practice Guidelines for Diagnosis, Treatment and Follow-up
- (2020) G. Argiles et al. ANNALS OF ONCOLOGY
- Clinical utility of tumour marker velocity of cancer antigen 15–3 (CA 15–3) and carcinoembryonic antigen (CEA) in breast cancer surveillance
- (2020) J.X. Hing et al. BREAST
- Serial circulating tumour DNA analysis for locally advanced rectal cancer treated with preoperative therapy: prediction of pathological response and postoperative recurrence
- (2020) Satoshi Murahashi et al. BRITISH JOURNAL OF CANCER
- ctDNA applications and integration in colorectal cancer: an NCI Colon and Rectal–Anal Task Forces whitepaper
- (2020) Arvind Dasari et al. Nature Reviews Clinical Oncology
- Association of Circulating Tumor DNA and Circulating Tumor Cells After Neoadjuvant Chemotherapy With Disease Recurrence in Patients With Triple-Negative Breast Cancer
- (2020) Milan Radovich et al. JAMA Oncology
- Circulating Tumor DNA as a Preoperative Marker of Recurrence in Patients with Peritoneal Metastases of Colorectal Cancer: A Clinical Feasibility Study
- (2020) Jamie J. Beagan et al. Journal of Clinical Medicine
- Clinical relevance of blood-based ctDNA analysis: mutation detection and beyond
- (2020) Laura Keller et al. BRITISH JOURNAL OF CANCER
- Serial circulating tumor DNA in predicting and monitoring the effect of neoadjuvant chemoradiotherapy in patients with rectal cancer: a prospective multicenter study
- (2020) Jiaolin Zhou et al. CLINICAL CANCER RESEARCH
- Comparison of variant allele frequency and number of mutant molecules as units of measurement for circulating tumor DNA
- (2020) Manouk K. Bos et al. Molecular Oncology
- Prognostic and predictive value of circulating tumor DNA during neoadjuvant chemotherapy for triple negative breast cancer
- (2020) Luca Cavallone et al. Scientific Reports
- Adjuvant Chemotherapy for Stage III Colon Cancer
- (2020) Julien Taieb et al. Cancers
- Hyperprogression: A novel response pattern under immunotherapy
- (2020) Xue‐jiao Han et al. Clinical and Translational Medicine
- Novel patterns of response under immunotherapy
- (2019) E Borcoman et al. ANNALS OF ONCOLOGY
- Pre-operative ctDNA predicts survival in high-risk stage III cutaneous melanoma patients
- (2019) J H Lee et al. ANNALS OF ONCOLOGY
- Circulating Tumor DNA as a Clinical Test in Resected Pancreatic Cancer
- (2019) Vincent P Groot et al. CLINICAL CANCER RESEARCH
- Personalized detection of circulating tumor DNA antedates breast cancer metastatic recurrence
- (2019) R. Charles Coombes et al. CLINICAL CANCER RESEARCH
- Early Detection of Metastatic Relapse and Monitoring of Therapeutic Efficacy by Ultra-Deep Sequencing of Plasma Cell-Free DNA in Patients With Urothelial Bladder Carcinoma
- (2019) Emil Christensen et al. JOURNAL OF CLINICAL ONCOLOGY
- Analysis of DNA Damage Response Gene Alterations and Tumor Mutational Burden Across 17,486 Tubular Gastrointestinal Carcinomas: Implications for Therapy
- (2019) Aparna R. Parikh et al. ONCOLOGIST
- The impact of pathologic response to neoadjuvant chemotherapy on conditional survival among patients with muscle-invasive bladder cancer
- (2019) Nikhil Waingankar et al. UROLOGIC ONCOLOGY-SEMINARS AND ORIGINAL INVESTIGATIONS
- Prognostic Potential of Circulating Tumor DNA Measurement in Postoperative Surveillance of Nonmetastatic Colorectal Cancer
- (2019) Yuxuan Wang et al. JAMA Oncology
- Analysis of Plasma Cell-Free DNA by Ultradeep Sequencing in Patients With Stages I to III Colorectal Cancer
- (2019) Thomas Reinert et al. JAMA Oncology
- Microsatellite Instability and Adjuvant Chemotherapy in Stage II Colon Cancer
- (2019) Julie L. Koenig et al. AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS
- Assessment of Molecular Relapse Detection in Early-Stage Breast Cancer
- (2019) Isaac Garcia-Murillas et al. JAMA Oncology
- European Association of Urology Guidelines on Non-muscle-invasive Bladder Cancer (TaT1 and Carcinoma In Situ) - 2019 Update
- (2019) Marko Babjuk et al. EUROPEAN UROLOGY
- Progress in cancer survival, mortality, and incidence in seven high-income countries 1995–2014 (ICBP SURVMARK-2): a population-based study
- (2019) Melina Arnold et al. LANCET ONCOLOGY
- LBA30_PRAnalysis of circulating tumour DNA (ctDNA) from patients enrolled in the IDEA-FRANCE phase III trial: Prognostic and predictive value for adjuvant treatment duration
- (2019) J Taieb et al. ANNALS OF ONCOLOGY
- Targeted next-generation sequencing of circulating-tumor DNA for tracking minimal residual disease in localized colon cancer
- (2019) N Tarazona et al. ANNALS OF ONCOLOGY
- Phase II Study Evaluating the Mechanisms of Resistance on Tumor Tissue and Liquid Biopsy in Patients With EGFR-mutated Non-pretreated Advanced Lung Cancer Receiving Osimertinib Until and Beyond Radiologic Progression: The MELROSE Trial
- (2019) Jaafar Bennouna et al. Clinical Lung Cancer
- Multigene assays in early breast cancer: Insights from recent phase 3 studies
- (2019) C. Markopoulos et al. EJSO
- Circulating Tumor DNA Analyses as Markers of Recurrence Risk and Benefit of Adjuvant Therapy for Stage III Colon Cancer
- (2019) Jeanne Tie et al. JAMA Oncology
- MRI Tumor Regression Grade and Circulating Tumor DNA as Complementary Tools to Assess Response and Guide Therapy Adaptation in Rectal Cancer
- (2019) Shelize Khakoo et al. CLINICAL CANCER RESEARCH
- RAS mutation analysis in circulating tumor DNA from patients with metastatic colorectal cancer: the AGEO RASANC prospective multicenter study
- (2018) J B Bachet et al. ANNALS OF ONCOLOGY
- Preoperative Circulating Tumor DNA in Patients with Peritoneal Carcinomatosis is an Independent Predictor of Progression-Free Survival
- (2018) Joel M. Baumgartner et al. ANNALS OF SURGICAL ONCOLOGY
- Association Between Circulating Tumor DNA and Pseudoprogression in Patients With Metastatic Melanoma Treated With Anti–Programmed Cell Death 1 Antibodies
- (2018) Jenny H. Lee et al. JAMA Oncology
- The Clinical Significance of Breast-only and Node-only Pathologic Complete Response (pCR) After Neoadjuvant Chemotherapy (NACT)
- (2018) Oluwadamilola M. Fayanju et al. ANNALS OF SURGERY
- Impact of baseline serum lactate dehydrogenase concentration on the efficacy of pembrolizumab and ipilimumab in patients with advanced melanoma: data from KEYNOTE-006
- (2017) G.V. Long et al. EUROPEAN JOURNAL OF CANCER
- iRECIST: guidelines for response criteria for use in trials testing immunotherapeutics
- (2017) Lesley Seymour et al. LANCET ONCOLOGY
- Phylogenetic ctDNA analysis depicts early-stage lung cancer evolution
- (2017) Christopher Abbosh et al. NATURE
- False-Positive Elevations of Carcinoembryonic Antigen in Patients With a History of Resected Colorectal Cancer
- (2017) Anya Litvak et al. Journal of the National Comprehensive Cancer Network
- The diagnostic accuracy of carcinoembryonic antigen to detect colorectal cancer recurrence – A systematic review
- (2016) Caspar G. Sørensen et al. International Journal of Surgery
- Serial monitoring of circulating tumor DNA in patients with primary breast cancer for detection of occult metastatic disease
- (2015) Eleonor Olsson et al. EMBO Molecular Medicine
- Cerebrospinal fluid-derived circulating tumour DNA better represents the genomic alterations of brain tumours than plasma
- (2015) Leticia De Mattos-Arruda et al. Nature Communications
- Risk of recurrence in patients with colon cancer stage II and III: A systematic review and meta-analysis of recent literature
- (2014) Camilla Böckelman et al. ACTA ONCOLOGICA
- Promoting Quality and Evidence-Based Care in Early-Stage Breast Cancer Follow-up
- (2014) L. N. Henry et al. JNCI-Journal of the National Cancer Institute
- Detection of Circulating Tumor DNA in Early- and Late-Stage Human Malignancies
- (2014) C. Bettegowda et al. Science Translational Medicine
- Pathological Complete Response and Accelerated Drug Approval in Early Breast Cancer
- (2012) Tatiana M. Prowell et al. NEW ENGLAND JOURNAL OF MEDICINE
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationCreate your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create Now